Table 2.
Antihypertensive Medication Usage
| All (N=7887) | Quartile 1 (<0.51) | Quartile 2 (0.51–1.39) | Quartile 3 (1.40–3.70) | Quartile 4 (>3.70) | P Value | |
|---|---|---|---|---|---|---|
| (n=2180) | (n=1997) | (n=1736) | (n=1974) | |||
| Diuretics/natriuretic, % a | 68 | 70 | 65 | 65 | 70 | <.001 |
| RAS blocker, % b | 54 | 59 | 50 | 48 | 58 | <.001 |
| RAS suppressor, % c | 51 | 68 | 54 | 41 | 39 | <.001 |
| Any medication, % | 83 | 88 | 81 | 80 | 84 | <.001 |
aDiuretics/natriuretic: aldosterone receptor blockers, thiazide diuretics, calcium channel blockers, α‐blockers, and loop diuretics. bRenin‐angiotensin system (RAS) blockers: angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers. cRAS suppressors: β‐receptor blockers, centrally acting α‐antagonists (guanfacine and clonidine) reserpine, methyldopa, and direct renin inhibitors. The majority of the plasma renin activity cohort was taking antihypertensive medication (83%). Diuretic/natriuretics were the most frequently used medication, which was consistent with Kaiser Permanente Southern California hypertension treatment guidelines during the observation period.